Search results for "Blood biomarkers"

showing 6 items of 6 documents

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

2018

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologyBlood biomarkersbusiness.industryInternal medicinemedicineNivolumabbusinessJournal of Thoracic Oncology
researchProduct

Use of Saliva in Alternative to Serum Sampling to Monitor Biomarkers Modifications in Professional Soccer Players

2018

We aimed to investigate the correlation between serum and salivary concentrations of steroid hormones and IgA, and the variation in concentrations of these biomarkers, across a soccer competitive season in a sample of players playing for an Italian major League team. Thirty-five elite male soccer players were recruited and assessed for salivary hormones (cortisol, testosterone, T/C‰ and DHEA-S) and IgA at three different time-points: (t1) after the pre-season period and 16 official matches played; (t2) after a winter break and three official matches played; (t3) 2 days after the final match of the championship and 19 matches played. Players were also tested for blood biomarkers (ser-C, ser-…

SalivaPhysiologyPhysiology030204 cardiovascular system & hematologySettore MED/42 - Igiene Generale E ApplicataPositive correlationlcsh:Physiologysalivary and serum hormones correlationsoccer playerscompetitive sports03 medical and health sciences0302 clinical medicinesalivary biomarkerssalivary testosteronePhysiology (medical)rest intervalMedicineTestosteroneOriginal ResearchRank correlationlcsh:QP1-981Free testosteronebusiness.industrysalivary hormones variationExercise in professional soccerResistance Training030229 sport sciencessalivary cortisolBlood biomarkersAnalysis of variancebusinesshuman activitiesIgAHormoneFrontiers in Physiology
researchProduct

ST elevāciju miokarda infarkta noteicošās artērijas intravaskulārās ultraskaņas audu raksturojuma saistība ar aterosklerozes asins biomarķieriem un s…

2013

Anotācija ST elevāciju miokarda infarkta gadījumā (STEMI) patofizioloģiskais substrāts ir rupturējusi vai erodējusi panga un tromboze. Šajā darbā veicām iMap IVUS audu analīzi STEMI mērķa bojājumiem 75 pacientiem, noteicām asinīs aterosklerozes biomarķierus un veicām 10 mēnešu apsekojumu. Mūsu rezultāti parādīja augstu nekrotisko audu daudzumu mērķa bojājumā un augstu, bet salīdzinoši zemāku, proksimālajā segmentā. Proksimālajā segmentā 10 mēnešu laikā samazinājās lipīdu audu daudzums par 10,2%. Neointimai 10 mēnešus pēc stenta implantācijas bija raksturīgs stabilāks audu sastāvs pēc iMap IVUS nekā natīvai aterosklerotiskai pangai šajā artērijā. Asins aterosklerozes biomarķieru saistību ar …

STEMIiMap intravaskulārā ultraskaņaaterosklerozes asins biomarķierineoatherosclerosisMedicineneoaterosklerozeMedicīna un farmācijaST elevāciju miokarda infarktsiMap intravascular ultrasoundVeselības aprūpeatherosclerosis blood biomarkersMedicīna
researchProduct

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients

2019

Background: We investigated whether early dynamic changes of circulating free (cfDNA) levels as well as the neutrophil to lymphocyte ratio (NLR) could predict nivolumab effectiveness in pretreated patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 45 patients receiving nivolumab 3 mg/kg every 2 weeks were enrolled. Patients underwent a computed tomography scan and responses were evaluated by the response evaluation criteria in solid tumors. Peripheral blood samples were obtained from the patients and the cfDNA level as well as the NLR were assessed. Time to progression (TTP) and overall survival (OS) were determined. Results: Patients with increased cfDNA >20%…

0301 basic medicineOncologymedicine.medical_specialtySettore MED/06 - Oncologia Medicamedicine.medical_treatmentnon-small cell lung cancer (NSCLC)Circulating free DNA (cfDNA)blood-based biomarkers; Circulating free DNA (cfDNA); immunotherapy; neutrophil to lymphocyte ratio (NLR); non-small cell lung cancer (NSCLC)lcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineNeutrophil to lymphocyte ratioOriginal Researchblood-based biomarkerbusiness.industryBlood based biomarkersblood-based biomarkersImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseneutrophil to lymphocyte ratio (NLR)non-small cell lung cancer (NSCLC)030104 developmental biologyOncologyBlood biomarkers030220 oncology & carcinogenesisimmunotherapyNivolumabbusiness
researchProduct

Oxidized Albumin and Cartilage Acidic Protein-1 as Blood Biomarkers to Predict Ischemic Stroke Outcomes.

2021

Background: There is high demand for blood biomarkers that reflect the therapeutic response or predict the outcomes of patients with acute ischemic stroke (AIS); however, few biomarkers have been evidentially verified to date. This study evaluated two proteins, oxidized albumin (OxHSA) and cartilage acidic protein-1 (CRTAC1), as potential prognostic markers of AIS.Methods: The ratio of OxHSA to normal albumin (%OxHSA) and the level of CRTAC1 in the sera of 74 AIS patients were analyzed on admission (day 0), and at 1 and 7 days after admission. AIS patients were divided into two groups according to their modified Rankin Scale (mRS) at 3 months after discharge: the low-mRS (mRS < 2) gr…

medicine.medical_specialtyacute ischemic strokebiomarker (BM)GastroenterologyModified Rankin ScaleInternal medicineMedicineoxidative stressCartilage acidic protein 1LC-MS/MSRC346-429Acute ischemic strokeOriginal Researchmass spectrometrybusiness.industrycartilage acidic protein-1AlbuminAfter dischargenervous systemNeurologyBlood biomarkersIschemic strokeNormal albuminNeurology. Diseases of the nervous systemNeurology (clinical)businessoxidized albuminFrontiers in neurology
researchProduct

Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease.

2011

Biomarkers are becoming increasingly important in the clinical management of complex diseases, yet our ability to discover new biomarkers remains limited by our dependence on endogenous molecules. Here we describe the development of exogenously administered 'synthetic biomarkers' composed of mass-encoded peptides conjugated to nanoparticles that leverage intrinsic features of human disease and physiology for noninvasive urinary monitoring. These protease-sensitive agents perform three functions in vivo: they target sites of disease, sample dysregulated protease activities and emit mass-encoded reporters into host urine for multiplexed detection by mass spectrometry. Using mouse models of li…

Liver CirrhosisUrinary systemBiomedical EngineeringEarly detectionBioengineeringComputational biologyDiseaseBiology010402 general chemistry01 natural sciencesApplied Microbiology and BiotechnologyMass SpectrometryArticle03 medical and health sciencesMiceIn vivoNeoplasmsmedicineAnimalsHumansAmino Acid SequenceBiomarker discovery030304 developmental biologyMonitoring Physiologic0303 health sciencesCancermedicine.disease3. Good health0104 chemical sciencesDisease Models AnimalBlood biomarkersImmunologyMolecular MedicineNanoparticlesCore biopsyBiomarkersBiotechnologyPeptide HydrolasesNature biotechnology
researchProduct